Executive Summary
The eight contracts analyzed, totaling $2.17 billion, are overwhelmingly civilian in nature (six of eight), with only two defense-related awards. The dominant theme is stable, long-duration civilian agency spending, led by a massive $892.8 million MAXIMUS contract with the Department of Education for debt management services, which alone accounts for 41% of total obligation.
The highest-conviction signal is the MAXIMUS win, a full-and-open competition that strengthens its competitive moat in government financial services. A key risk is the concentration of revenue in the MAXIMUS contract and the lumpy, short-duration $106 million OptumRx VA awards, which introduce execution and revenue visibility concerns.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Tracking the trend? Catch up on the prior Significant Contract Modifications ($10M+) digest from August 21, 2026.
Investment Signals (5)
- MAXIMUS Wins $892.8M Department of Education Contract – Dominant Civilian Win (HIGH)▲
MAXIMUS FEDERAL SERVICES secured a $892.8 million firm-fixed-price contract for debt management systems, awarded under full-and-open competition, signaling strong market position and long-term revenue visibility through July 2026.
- Navarro Research Secures $427.6M DOE Legacy Management Contract – Small Business Moat (MEDIUM)▲
Navarro Research and Engineering won a $427.6 million cost-plus-award-fee contract from DOE, leveraging its small disadvantaged business status to create a competitive moat in environmental remediation services.
- General Dynamics' Gulfstream Wins $251M NOAA Aircraft Contract – Stable Defense/Aviation Backlog (MEDIUM)▲
Gulfstream Aerospace (General Dynamics) secured a $251.1 million sole-source contract for G550 aircraft, strengthening its government aviation backlog with a 9-year performance period through 2028.
- Fort Myer Construction Wins $173M DOT Highway Project – Infrastructure Execution Strength (MEDIUM)▲
Fort Myer Construction Corp won a $173 million fixed-price contract with economic price adjustment for highway reconstruction, with $161M already outlaid, indicating strong execution and cash flow visibility.
- OptumRx Wins Two $106M VA PBM Delivery Orders – Short-Term Revenue Catalyst (MEDIUM)▲
UnitedHealth Group's OptumRx won two $106.3 million firm-fixed-price delivery orders from the VA for pharmacy benefit management, each covering a single quarter, creating a near-term revenue catalyst but with lumpy recognition.
Risk Flags (4)
- Concentration [HIGH RISK]▼
MAXIMUS contract ($892.8M) represents 41% of total obligation, creating significant revenue concentration risk for the company if the contract is modified or not renewed.
- Execution [MEDIUM RISK]▼
OptumRx's two $106M VA delivery orders are firm-fixed-price with no outlays yet, shifting cost risk to UnitedHealth Group and compressing margins if claims volume spikes.
- Budget [MEDIUM RISK]▼
The $427.6M Navarro Research contract has only $97.1M outlaid (23%), indicating potential budget execution risk or delayed revenue recognition for the remaining $330.5M.
- Competition [LOW RISK]▼
The $251M Gulfstream contract was awarded non-competitively, which may invite protests and limit competitive visibility for General Dynamics.
Opportunities (3)
- ◆
MAXIMUS's $892.8M Education contract demonstrates strong demand for outsourced debt management services, suggesting potential for follow-on awards or expansions in federal financial services.
- ◆
Navarro Research's $427.6M DOE contract as a small disadvantaged business highlights the competitive advantage of set-aside programs, which could be replicated by other qualified firms.
- ◆
Gulfstream's $251M NOAA contract for G550 aircraft signals potential for similar sole-source awards from other civilian agencies, expanding General Dynamics' government aviation footprint.
Sector Themes (3)
- ◆
Six of eight contracts are civilian, with the MAXIMUS ($892.8M) and Navarro ($427.6M) awards spanning over a decade, indicating sustained federal investment in debt management and environmental remediation.
- ◆
Fort Myer Construction's $173M highway reconstruction contract, with $161M already outlaid, reflects strong execution in federal infrastructure projects under full-and-open competition.
- ◆
OptumRx's two $106M VA delivery orders for PBM services indicate consistent federal spending on healthcare administration, though short-duration awards create lumpy revenue.
Watch List (4)
- 👁
{"entity" => "MAXIMUS INC", "reason" => "Largest contract ($892.8M) with 41% concentration; monitor contract performance and renewal prospects.", "trigger" => "Contract end date July 2026; Department of Education budget announcements"}
- 👁
{"entity" => "UnitedHealth Group Incorporated", "reason" => "Two $106M VA PBM delivery orders with no outlays yet; execution risk and lumpy revenue.", "trigger" => "VA Q2-Q4 FY25 PBM award announcements; Q1 2026 earnings"}
- 👁
{"entity" => "General Dynamics", "reason" => "$251M Gulfstream contract with sole-source award; potential for protests or modifications.", "trigger" => "NOAA aircraft procurement updates; contract modification announcements"}
- 👁
{"entity" => "Navarro Research and Engineering, Inc.", "reason" => "$427.6M contract with only 23% outlaid; budget execution risk.", "trigger" => "DOE Office of Legacy Management budget; outlay rate changes"}
Get daily alerts with 5 investment signals, 4 risk alerts, 3 opportunities and full AI analysis of all 8 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: Significant Contract Modifications ($10M+)
August 20, 2026
Significant Contract Modifications ($10M+) — August 20, 2026
August 19, 2026
Significant Contract Modifications ($10M+) — August 19, 2026
August 18, 2026
Significant Contract Modifications ($10M+) — August 18, 2026
August 16, 2026
Significant Contract Modifications ($10M+) — August 16, 2026
🇺🇸 More from United States
View all →August 22, 2026
New Drug Approvals (Original) — August 22, 2026
New Drug Approvals (Original)
August 22, 2026
Orphan Drug Approvals — August 22, 2026
Orphan Drug Approvals
August 22, 2026
Big Pharma Approvals — August 22, 2026
Big Pharma Approvals
August 22, 2026
NME Blockbuster Approvals — August 22, 2026
NME Blockbuster Approvals